Literature DB >> 8995540

Stage IV ovarian cancer: impact of surgical debulking.

J P Curtin1, R Malik, E S Venkatraman, R R Barakat, W J Hoskins.   

Abstract

OBJECTIVE: To evaluate the influence of surgical debulking performed on patients with Stage IV ovarian cancer and to determine prognostic factors which identify pts who may benefit from aggressive initial surgical debulking.
METHODS: A retrospective chart review was conducted (1/1/87-12/31/93). Eligible patients included all women with FIGO Stage IV ovarian cancer. Clinical information abstracted included age at diagnosis, histology type, tumor grade, criteria for Stage IV classification, surgical procedure performed, and tumor residuum. Optimal surgical status was defined as < or = 2 cm residual disease. Chemotherapy treatment was recorded, as was follow-up. Survival estimates were computed by Kaplan-Meier method with differences in survival calculated by the log-rank test. The Cox proportional hazards regression model was used to identify independent variables which were associated with an improved survival rate.
RESULTS: One hundred five women were found in our database with Stage IV ovarian cancer and 97 had complete information available. Median age of the patients was 57 years (range 24-81 years). Papillary-serous histology was found in 55/97 patients (57%) and 50 patients (52%) had grade 3 tumors. Forty-one of 97 patients (42%) had malignant pleural effusion and 20/97 (21%) had liver metastases. Ninety-two patients underwent a primary attempt at surgical debulking and 40/92 were optimally debulked. Twenty-one of 41 patients (51%) with pleural effusion were optimally debulked compared to 20/51 (39%) with other criteria for Stage IV disease (P = NS). Overall median survival was 21 months; optimally debulked patients' median survival was 40 months compared to 18 months for patients with bulky residual disease (P = 0.01). The survival advantage for optimally debulked patients was statistically significant for the two subgroups of patients with and without malignant pleural effusion. In the multivariate analysis only age less than 65 years and optimal debulking were independent predictors of outcome.
CONCLUSIONS: Surgical debulking appears to be an important determinant of prognosis in women with Stage IV ovarian cancer, including patients with malignant pleural effusion.

Entities:  

Mesh:

Year:  1997        PMID: 8995540     DOI: 10.1006/gyno.1996.4550

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

1.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

2.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; Moune Jabre-Raughley; Amy K Brown; Katina M Robison; M Craig Miller; W Jeffery Allard; Robert J Kurman; Robert C Bast; Steven J Skates
Journal:  Am J Obstet Gynecol       Date:  2010-05-14       Impact factor: 8.661

Review 3.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Authors:  Lele Shashikant; P Kesterson Joshua
Journal:  J Obstet Gynaecol India       Date:  2009 May-Jun

5.  Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.

Authors:  Emma L Barber; Stacie B Dusetzina; Karyn B Stitzenberg; Emma C Rossi; Paola A Gehrig; John F Boggess; Joanne M Garrett
Journal:  Gynecol Oncol       Date:  2017-03-31       Impact factor: 5.482

Review 6.  Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.

Authors:  Jing-Yi Chern; John P Curtin
Journal:  Curr Treat Options Oncol       Date:  2016-01

7.  Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Authors:  Karin K Shih; Dennis S Chi
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

8.  Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival.

Authors:  Oleg Mironov; Nicole M Ishill; Svetlana Mironov; Hebert Alberto Vargas; Junting Zheng; Chaya S Moskowitz; Yukio Sonoda; Ralph S Papas; Dennis S Chi; Hedvig Hricak
Journal:  Radiology       Date:  2010-12-30       Impact factor: 11.105

9.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

10.  Hepatic resection for metachronous metastases from ovarian carcinoma.

Authors:  Jesus Gonzalez Bosquet; Melissa A Merideth; Karl C Podratz; David M Nagorney
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.